Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/11113
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | McMahon, L P | en |
dc.contributor.author | Dawborn, J K | en |
dc.date.accessioned | 2015-05-16T00:42:02Z | |
dc.date.available | 2015-05-16T00:42:02Z | |
dc.date.issued | 1990-05-16 | en |
dc.identifier.citation | American Journal of Nephrology; 10(5): 404-8 | en |
dc.identifier.govdoc | 2080791 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/11113 | en |
dc.description.abstract | Twelve stable haemodialysis patients were divided into two groups and given recombinant human erythropoietin (r-HuEPO) for 14 weeks either intravenously (i.v.) or subcutaneously (s.c.). Dosage was 25 units/kg either thrice (i.v.) or twice (s.c.) per week for 7 weeks, and then 50 units/kg for a further 7 weeks. Response to s.c. therapy was comparable to i.v. despite a 33% lower weekly dosage, and was significant at both 7 (i.v.: 1.1 +/- 0.3, mean +/- SEM, p = 0.02; s.c.: 0.8 +/- 0.3 g/dl, p = 0.03) and 14 weeks (i.v.: 2.8 +/- 0.5, p = 0.003; s.c.: 2.6 +/- 0.6 g/dl, p = 0.009). A correlation was observed between response to r-HuEPO and initial ferritin levels (r = 0.63, p = 0.04). One patient required an increase in antihypertensive medication and there was one arteriovenous fistula thrombosis. Results suggest that overall s.c. therapy is as effective as i.v. therapy, and that a good response with few side effects can be obtained using relatively low doses of r-HuEPO. | en |
dc.language.iso | en | en |
dc.subject.other | Anemia.drug therapy.etiology | en |
dc.subject.other | Drug Administration Schedule | en |
dc.subject.other | Erythropoietin.administration & dosage.therapeutic use | en |
dc.subject.other | Female | en |
dc.subject.other | Humans | en |
dc.subject.other | Injections, Intravenous | en |
dc.subject.other | Injections, Subcutaneous | en |
dc.subject.other | Kidney Failure, Chronic.complications.therapy | en |
dc.subject.other | Male | en |
dc.subject.other | Recombinant Proteins.administration & dosage.therapeutic use | en |
dc.subject.other | Renal Dialysis | en |
dc.title | Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | American journal of nephrology | en |
dc.identifier.affiliation | Department of Medicine, Austin Hospital, Heidelberg, Victoria. | en |
dc.description.pages | 404-8 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/2080791 | en |
dc.type.austin | Journal Article | en |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.